Navigation Links
E. coli engineered to produce important class of antibiotic, anti-cancer drugs
Date:12/22/2008

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have taken a major step forward in the field of metabolic engineering, successfully using the bacterium Escherichia coli to synthesize a class of natural products known bacterial aromatic polyketides, which include important antibiotic and anticancer drugs.

Natural products are pharmacologically or biologically potent chemical compounds produced by living organisms; many are the active ingredients in pharmaceuticals. Bacterial aromatic polyketides include the antibiotic tetracycline and the compound doxorubicin, used in the treatment of breast and other cancers.

Because many of these natural products are synthesized by organisms that are difficult to collect, grow and maintain, researchers have sought to produce them using simpler organisms like E. coli, whose fast growth, variety of genetic tools and well-understood metabolism make it an ideal host for engineering and mass producing these compounds.

While turning E. coli into a microbial factory for natural products has been highly successful, resulting in the production of groups of drugs that include antibiotics like erythromycin and vancomycin, as well as terpenes and alkaloids, attempts to synthesize bacterial aromatic polyketides had previously been hindered by the compounds' complicated assembly process.

To achieve the successful synthesis of the aromatic polyketides, the UCLA research team which included principal investigator Yi Tang, an associate professor of chemical and biomolecular engineering, and graduate students Wenjun Zhang and Yanran Li first dissected a polyketide synthase enzyme from a rice plant fungus, then reassembled it and transferred it into the E. coli bacterium. The resulting synthetic enzyme is necessary to synthesize the carbon backbone of aromatic polyketides, which was previously inaccessible in E. coli.

In addition to the synthetic enzyme, the researchers introduced other enzymes to form a new pathway in E. coli that produced a range of bacterial aromatic polyketides from simple nutrients such as glucose.

"This is a key advance in the field of natural product biosynthesis," said Tang of the research, which will be published Dec. 30 in Proceedings of the National Academy of Sciences and is currently available on the journal's website. "We have now outfitted E. coli with the ability to make this family of compounds that are vital toward treating diseases such as infectious diseases and cancer.

"Furthermore, we can now take advantage of the E. coli machinery to engineer the pathways we introduced and synthesize new versions of natural products that may be more potent than the current versions - so-called unnatural natural products."

On a more fundamental level, the UCLA researchers are exploring interactions between the bacterial and fungal components they introduced into E. coli, which are from different kingdoms of life.

"There are some beliefs that bacterial and fungal enzymes will not cross-talk to each other," said Zhang, the paper's lead author. "Our work showed that polyketide synthase from the two kingdoms can indeed be functionally combined inside the E. coli platform. Therefore, there is much to learn about why these interactions are possible."


'/>"/>

Contact: Matthew Chin
mchin@support.ucla.edu
310-206-0680
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
3. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
4. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
5. Reconstructing mandibular defects with bioengineered tooth and bone
6. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
7. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
8. Tumor suppressor genes speed up and slow down aging in engineered mouse
9. FDA Proposes Regulations for Genetically Engineered Animals
10. Top Athletes Join Forces for a New Mission: Athlete-Engineered Skincare to Support Performance and Benefit Charity
11. Whiplash may produce delayed jaw pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: